Jefferies Group Comments on Marrone Bio Innovations Inc’s FY2022 Earnings (MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) – Equities research analysts at Jefferies Group issued their FY2022 earnings estimates for shares of Marrone Bio Innovations in a research note issued on Thursday. Jefferies Group analyst L. Alexander forecasts that the basic materials company will post earnings per share of $0.03 for the year.

A number of other analysts have also recently weighed in on MBII. HC Wainwright set a $4.00 price target on Marrone Bio Innovations and gave the stock a “buy” rating in a research report on Thursday, December 21st. ValuEngine raised Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. Marrone Bio Innovations currently has a consensus rating of “Hold” and a consensus price target of $2.50.

Shares of Marrone Bio Innovations (MBII) traded up $0.06 during trading hours on Friday, hitting $1.24. The company’s stock had a trading volume of 145,525 shares, compared to its average volume of 102,936. Marrone Bio Innovations has a 12 month low of $0.85 and a 12 month high of $2.30. The firm has a market capitalization of $40.85, a PE ratio of -1.08 and a beta of 0.26. The company has a quick ratio of 0.36, a current ratio of 0.69 and a debt-to-equity ratio of -1.14.

Marrone Bio Innovations (NASDAQ:MBII) last announced its quarterly earnings results on Monday, November 13th. The basic materials company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The business had revenue of $4.22 million during the quarter, compared to the consensus estimate of $5.32 million.

In other Marrone Bio Innovations news, insider Ardsley Advisory Partners acquired 6,666,667 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was acquired at an average price of $0.75 per share, with a total value of $5,000,000.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.80% of the stock is currently owned by insiders.

A hedge fund recently raised its stake in Marrone Bio Innovations stock. Ardsley Advisory Partners increased its holdings in shares of Marrone Bio Innovations Inc (NASDAQ:MBII) by 375.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 3,681,580 shares of the basic materials company’s stock after purchasing an additional 2,907,142 shares during the period. Ardsley Advisory Partners owned approximately 11.74% of Marrone Bio Innovations worth $4,528,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 37.59% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Comments on Marrone Bio Innovations Inc’s FY2022 Earnings (MBII)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2018/02/10/jefferies-group-comments-on-marrone-bio-innovations-incs-fy2022-earnings-mbii.html.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply